MX2022003699A - Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206. - Google Patents

Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206.

Info

Publication number
MX2022003699A
MX2022003699A MX2022003699A MX2022003699A MX2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A
Authority
MX
Mexico
Prior art keywords
mannosylated
blocking
backbone
dextrans
ligands
Prior art date
Application number
MX2022003699A
Other languages
English (en)
Spanish (es)
Inventor
David A Ralph
Jeffrey Arnold
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of MX2022003699A publication Critical patent/MX2022003699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MX2022003699A 2019-09-30 2020-09-30 Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206. MX2022003699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908136P 2019-09-30 2019-09-30
PCT/US2020/053604 WO2021067479A1 (en) 2019-09-30 2020-09-30 Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands

Publications (1)

Publication Number Publication Date
MX2022003699A true MX2022003699A (es) 2022-07-13

Family

ID=75337533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003699A MX2022003699A (es) 2019-09-30 2020-09-30 Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206.

Country Status (7)

Country Link
US (1) US20210145989A1 (cg-RX-API-DMAC10.html)
EP (1) EP4021459A4 (cg-RX-API-DMAC10.html)
JP (1) JP7599727B2 (cg-RX-API-DMAC10.html)
CN (1) CN115151264B (cg-RX-API-DMAC10.html)
CA (1) CA3155675A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022003699A (cg-RX-API-DMAC10.html)
WO (1) WO2021067479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CN114894698B (zh) * 2022-04-15 2023-02-03 广东省第二人民医院(广东省卫生应急医院) MDSCs在再生障碍性贫血诊断和/或分型中的应用
US20240024491A1 (en) * 2022-07-13 2024-01-25 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624046A (en) * 1982-01-04 1986-11-25 Fairchild Camera & Instrument Corp. Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
JP3582234B2 (ja) * 1996-05-20 2004-10-27 ニプロ株式会社 IgA腎症特異的フィブロネクチン断片、その検出方法およびキット
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
EP1501522A4 (en) * 2002-05-06 2007-12-05 Univ Utah Res Found PRE-BLOCKING WITH NON-HA GAGS INCREASES THE EFFECTIVENESS OF HA-CONJUGATED CANCER
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
JP4543860B2 (ja) * 2004-09-30 2010-09-15 株式会社島津製作所 試料の解析方法
US20080182816A1 (en) * 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
HK1225623A1 (zh) * 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US20190021608A1 (en) * 2017-05-19 2019-01-24 Navidea Biopharmaceuticals, Inc. CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in Humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Also Published As

Publication number Publication date
JP2022550174A (ja) 2022-11-30
CN115151264A (zh) 2022-10-04
WO2021067479A1 (en) 2021-04-08
JP7599727B2 (ja) 2024-12-16
EP4021459A4 (en) 2023-09-27
EP4021459A1 (en) 2022-07-06
US20210145989A1 (en) 2021-05-20
CA3155675A1 (en) 2021-04-08
CN115151264B (zh) 2024-03-12

Similar Documents

Publication Publication Date Title
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
PH12021552482A1 (en) Compounds targeting prmt5
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4707394A3 (en) Rnai agents for hepatitis b virus infection
PH12020550065A1 (en) Hepatitis b antiviral agents
ME01600B (me) MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE
CY1117440T1 (el) Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2009132238A3 (en) Ido inhibitors
MX2009012093A (es) Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
WO2020033838A3 (en) Treatment of egfr-mutant cancer
WO2008005084A3 (en) Methods to prevent and treat diseases
MX2024003772A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2021007738A (es) Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
EP4021459A4 (en) COMPOSITIONS AND METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS
JP2013539776A5 (cg-RX-API-DMAC10.html)
AU2018306329A8 (en) Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020160453A8 (en) Modulators of yap1 expression
EP4245372A3 (en) Hbv inhibitor and use thereof
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2008030605A3 (en) Herv group ii viruses in lymphoma and cancer
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety